Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 36 Records) |
| Query Trace: Depressive Disorder and CYP2C19[original query] |
|---|
| Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital. Personalized medicine 2008 Nov 5 (6): 579-587. Ruaño Gualberto, Villagra David, Rahim Umme Salma, Windemuth Andreas, Kocherla Mohan, Bower Bruce, Szarek Bonnie L, Goethe John |
| The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. Journal of clinical pharmacy and therapeutics 2015 Sep . Uckun Z, Baskak B, Ozel-Kizil E T, Ozdemir H, Devrimci Ozguven H, Suzen H |
| Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients. International journal of clinical pharmacy 2016 Jan . Yuce-Artun Nazan, Baskak Bora, Ozel-Kizil Erguvan Tugba, Ozdemir Hatice, Uckun Zuhal, Devrimci-Ozguven Halise, Suzen Halit Sin |
| Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools. The pharmacogenomics journal 2018 5 18 (5): 613-622. Bousman Chad A, Dunlop Boadie |
| Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder. Pharmacogenomics 2018 Jan . Montané Jaime Lazara Karelia, Paul Jeffrey, Lalla Anthony, Legall George, Gaedigk Andr |
| Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Frontiers in pharmacology 2019 3 10 83. Veldic Marin, Ahmed Ahmed T, Blacker Caren J, Geske Jennifer R, Biernacka Joanna M, Borreggine Kristin L, Moore Katherine M, Prieto Miguel L, Vande Voort Jennifer L, Croarkin Paul E, Hoberg Astrid A, Kung Simon, Alarcon Renato D, Keeth Nicola, Singh Balwinder, Bobo William V, Frye Mark |
| No association between CYP2C19 genetic polymorphism with treatment remission to antidepressant venlafaxine in Han Chinese population. Psychiatric genetics 2019 Dec . Zhang Naixing, Ji Lei, Chen Zhixuan, An Lin, Ren Decheng, Bi Yan, Guo Zhenming, Yuan Ruixue, Yuan Fan, Dong Zaiquan, Yin Li, Sun Xueli, Yang Fengping, Li Xingwang, Yu Tao, He Lin, Shi Lei, He Gua |
| Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. Clinical pharmacology and therapeutics 2019 10 107 (3): 662-670. Qin Sisi, Eugene Andy R, Liu Duan, Zhang Lingxin, Neavin Drew, Biernacka Joanna M, Yu Jia, Weinshilboum Richard M, Wang Liew |
| A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. Drug development research 2019 Oct . Kanders Sofia H, Pisanu Claudia, Bandstein Marcus, Jonsson Jörgen, Castelao Enrique, Pistis Giorgio, Gholam-Rezaee Mehdi, Eap Chin B, Preisig Martin, Schiöth Helgi B, Mwinyi Jessi |
| CYP2C19 polymorphisms and outcomes of Escitalopram treatment in Brazilians with major depression. Heliyon 2020 May 6 (5): e04015. Bernini de Brito Rodrigo, Ghedini Paulo Cés |
| Subtherapeutic bupropion and hydroxybupropion serum concentrations in a patient with CYP2C19*1/*17 genotype suggesting a rapid metabolizer status. The pharmacogenomics journal 2020 Jun . Gaebler Arnim Johannes, Schneider Katharina Luise, Stingl Julia Carolin, Paulzen Micha |
| Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry 2020 Dec . Hahn Martina, Müller Daniel J, Roll Sibylle |
| Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. Frontiers in pharmacology 2021 12 688950. Matthaei Johannes, Brockmöller Jürgen, Steimer Werner, Pischa Konstanze, Leucht Stefan, Kullmann Maria, Jensen Ole, Ouethy Typhaine, Tzvetkov Mladen Vassilev, Rafehi Muhamm |
| Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin 2021 6 51 (2): 31-42. Zastrozhin M S, Skryabin VYu, Smirnov VYu, Zastrozhina A K, Kaverina E V, Klepikov D A, Grishina E A, Ryzhikova K A, Bure I V, Bryun E A, Sychev D |
| Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. Pharmacogenomics 2021 5 22 (8): 485-503. Shalimova Alena, Babasieva Viktoria, Chubarev Vladimir N, Tarasov Vadim V, Schiöth Helgi B, Mwinyi Jessi |
| Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder. Psychopharmacology bulletin 2021 4 51 (1): 69-80. Zastrozhin M S, Skryabin VYu, Smirnov VYu, Zastrozhina A K, Kaverina E V, Klepikov D A, Grishina E A, Ryzhikova K A, Bure I V, Bryun E A, Sychev D |
| Effects of CYP2C19 genetic polymorphism on the steady-state concentration of citalopram in patients with major depressive disorder. The pharmacogenomics journal 2021 Feb . Zastrozhin M S, Skryabin V Yu, Petukhov A E, Torrado M V, Pankratenko E P, Zastrozhina A K, Grishina E A, Ryzhikova K A, Shipitsyn V V, Bryun E A, Sychev D |
| First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2021 Jan 159 105724. Shen Qi, Hu Chao, Miao Jia, Chen Junxia, Peng Yueying, Pan Tingting, He Xiaolin, Yuan Jing, Ni Shaonan, Wang Yongsheng, Luo Z |
| Influence of CYP2C19*17 Genetic Polymorphism on the Steady-State Concentration of Escitalopram in Patients with Recurrent Depressive Disorder. Psychopharmacology bulletin 2022 06 52 (3): 8-19. Zastrozhin M S, Skryabin VYu, Rwere F, Petukhov A E, Pankratenko E P, Pozdniakov S A, Ivanchenko V A, Noskov V V, Zaytsev I A, Vinokurova N V, Horyaev D S, Vlasovskih R V, Bryun E A, Sychev D |
| [Association of SCN2A, ABCB1 and CYP2C19*3 with genetic susceptibility to major depressive disorder]. Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 2022 4 56 (3): 287-294. Zhang T, Rao Q M, He Y Y, Cai J T, Liu H Y, Lin Y |
| CYP2C19 slow metabolizer phenotype is associated with lower antidepressant efficacy and tolerability. Psychiatry research 2022 4 312 114535. Jokovi? Danilo, Milosavljevi? Filip, Stojanovi? Zvezdana, Šupi? Gordana, Vojvodi? Danilo, Uzelac Bojana, Juki? Marin M, Petkovi? ?ur?in Aleksand |
| Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2022 Mar 56 100-111. Calabrò Marco, Fabbri Chiara, Kasper Siegfried, Zohar Joseph, Souery Daniel, Montgomery Stuart, Albani Diego, Forloni Gianluigi, Ferentinos Panagiotis, Rujescu Dan, Mendlewicz Julien, De Ronchi Diana, Serretti Alessandro, Crisafulli Concet |
| The Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank. Pharmaceuticals (Basel, Switzerland) 2023 9 16 (9): . Win Lee Edwin Wong, Chiara Fabbri, Benjamin Laplace, Danyang Li, Roos van Westrhenen, Cathryn M Lewis, Gavin Stewart Dawe, Allan H You |
| Effect of CYP2C19 Pharmacogenetic Testing on Predicting Citalopram and Escitalopram Tolerability and Efficacy: A Retrospective, Longitudinal Cohort Study. Biomedicines 2023 12 11 (12): . Mahmood Mahajna, Rami Abu Fanne, Matitiahu Berkovitch, Elias Tannous, Shlomo Vinker, Ilan Green, Ilan Mat |
| Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study. Canadian journal of psychiatry. Revue canadienne de psychiatrie 2023 10 7067437231203433. Farhana Islam, Leen Magarbeh, Samar S M Elsheikh, Stefan Kloiber, Caroline W Espinola, Venkat Bhat, Benicio N Frey, Roumen Milev, Claudio N Soares, Sagar V Parikh, Franca Placenza, Stefanie Hassel, Valerie H Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W Lam, Gustavo Turecki, Jane A Foster, Susan Rotzinger, Sidney H Kennedy, Daniel J Müll |
| CYP2C19-rs4986893 confers risk to major depressive disorder and bipolar disorder in the Han Chinese population whereas ABCB1-rs1045642 acts as a protective factor. BMC psychiatry 2023 1 23 (1): 69. Zhang Ting, Rao Qingmin, Lin Kangguang, He Yongyin, Cai Jintai, Yang Mengxin, Xu Ying, Hou Le, Lin Yulong, Liu Haiyi |
| Common polygenic variation in the early medication change (EMC) cohort affects disorder risk, but not the antidepressant treatment response. Journal of affective disorders 2024 7 . Svenja Müller, Klaus Lieb, Fabian Streit, Swapnil Awasthi, Stefanie Wagner, Josef Frank, Marianne B Müller, André Tadic, Stefanie Heilmann-Heimbach, Per Hoffmann, Laven Mavarani, Börge Schmidt, Marcella Rietschel, Stephanie H Witt, Lea Zillich, Jan Engelma |
| Integrative Genetic Variation, DNA Methylation, and Gene Expression Analysis of Escitalopram and Aripiprazole Treatment Outcomes in Depression: A CAN-BIND-1 Study. Pharmacopsychiatry 2024 6 . Farhana Islam, Amanda Lisoway, Edward S Oh, Laura M Fiori, Leen Magarbeh, Samar S M Elsheikh, Helena K Kim, Stefan Kloiber, James L Kennedy, Benicio N Frey, Roumen Milev, Claudio N Soares, Sagar V Parikh, Franca Placenza, Stefanie Hassel, Valerie H Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W Lam, Gustavo Turecki, Jane A Foster, Susan Rotzinger, Sidney H Kennedy, Daniel J Müll |
| Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically-Based Pharmacokinetic Modeling and Clinical Observation. Clinical pharmacology and therapeutics 2024 12 . Yoo Jin Jang, Doh Kwan Kim, Shinn-Won Lim, Eunjin Ho |
| Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder. BMC psychiatry 2024 10 24 (1): 690. Dominika Jar?ušková, Ivan Tká?, Nataša Hlavá?ová, Alena Stan?áková Yaluri, Miriam Kozárová, Viera Habalová, Lucia Klim?áková, Jozef Židzik, Martin Javorský, Aneta Bedná?o |
- Page last reviewed:Feb 1, 2024
- Content source: